In its SEC filing, Allena Pharmaceuticals Inc (NASDAQ: ALNA) filed for chapter 11 bankruptcy protection and terminated the employment of substantially all of its employees.
In January, the company announced exploring strategic and financing alternatives.
The company terminated substantially all of its employees, including Louis Brenner, President and Chief Executive Officer of the Company, and Richard D. Katz, Chief Financial Officer.
The company said it intends to continue operating at a reduced level.
Allena expects the filing to cancel or extinguish all outstanding shares without any payment or other distribution.
After receiving a Nasdaq delisting warning, Allena requested a hearing, said it is unlikely to pursue the hearing, and expects its stock to be soon suspended.
Last month, the company signaled it lacks the financial resources to conduct studies for ALLN-346 for hyperuricemia and gout in the setting of advanced chronic kidney disease.
Earlier this year, Allena terminated the URIROX-2 study after the company believed separating the reloxaliase and placebo groups for the UOx primary endpoint was lower than expected.
Price Action: ALNA shares are down 9.36% at $0.09 during the premarket session on the last check Tuesday.
See more from Benzinga
CVS Health Expands Home Healthcare Portfolio With $8B Signify Health Acquisition
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
